Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31

BACKGROUND: National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tumor blocks from B-31....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Pogue-Geile, Katherine L., Kim, Chungyeul, Jeong, Jong-Hyeon, Tanaka, Noriko, Bandos, Hanna, Gavin, Patrick G., Fumagalli, Debora, Goldstein, Lynn C., Sneige, Nour, Burandt, Eike, Taniyama, Yusuke, Bohn, Olga L., Lee, Ahwon, Kim, Seung-Il, Reilly, Megan L., Remillard, Matthew Y., Blackmon, Nicole L., Kim, Seong-Rim, Horne, Zachary D., Rastogi, Priya, Fehrenbacher, Louis, Romond, Edward H., Swain, Sandra M., Mamounas, Eleftherios P., Wickerham, D. Lawrence, Geyer, Charles E., Costantino, Joseph P., Wolmark, Norman, Paik, Soonmyung
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3848987/
https://ncbi.nlm.nih.gov/pubmed/24262440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djt321
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak